ArticleCancer drug resistance (Alhambra, Calif.)2023

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates.

Santiago Escrivá-de-Romaní et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.